Sabina A Antoniu1. 1. University of Medicine and Pharmacy Gr. T Popa, Division of Pulmonary Disease, Pulmonary Disease University Hospital, 30 Dr I Cihac Street, 700115 Iasi, Romania. sabina.antonela.antoniu@pneum.umfiasi.ro
Abstract
BACKGROUND: In asthma, inhaled corticosteroids are not always able to maintain an optimal therapeutic control despite being used at high doses; other anti-inflammatory therapies are needed. Several such therapies, including daclizumab, are currently under evaluation. OBJECTIVE: To discuss the results of study on daclizumab in asthma patients. METHODS: Analysis of efficacy and safety data from a randomised placebo-controlled study performed in patients with moderate to severe asthma and suboptimal control under high doses of inhaled corticosteroids. CONCLUSIONS:Daclizumab demonstrated significant efficacy and its further clinical evaluation in asthma is supported by these results.
RCT Entities:
BACKGROUND: In asthma, inhaled corticosteroids are not always able to maintain an optimal therapeutic control despite being used at high doses; other anti-inflammatory therapies are needed. Several such therapies, including daclizumab, are currently under evaluation. OBJECTIVE: To discuss the results of study on daclizumab in asthmapatients. METHODS: Analysis of efficacy and safety data from a randomised placebo-controlled study performed in patients with moderate to severe asthma and suboptimal control under high doses of inhaled corticosteroids. CONCLUSIONS:Daclizumab demonstrated significant efficacy and its further clinical evaluation in asthma is supported by these results.
Authors: Umesh C S Yadav; Amarjit S Naura; Leopoldo Aguilera-Aguirre; Kota V Ramana; Istvan Boldogh; Sanjiv Sur; Hamid A Boulares; Satish K Srivastava Journal: J Immunol Date: 2009-09-14 Impact factor: 5.422
Authors: Soheil Moosavinasab; Jeremy Patterson; Robert Strouse; Majid Rastegar-Mojarad; Kelly Regan; Philip R O Payne; Yungui Huang; Simon M Lin Journal: Database (Oxford) Date: 2016-05-17 Impact factor: 3.451